Dexrazoxane (Totect™): FDA Review and Approval for the Treatment of Accidental Extravasation Following Intravenous Anthracycline Chemotherapy
13-4-445_Kane
|
CME Activity Information |
|
Release Date: |
April 30, 2008 |
|
Most Recent Review: |
April 30, 2008* |
|
Most Recent Update: |
April 30, 2008 |
|
Date Credit Expires: |
April 30, 2010 |
|
Time to Complete: |
1 hour |
|
Medium: |
Internet Online |
|
*Click here
to learn more about our review process. |
Instructions for Participation
- Read the following information before beginning the educational activity
and click the "Take this course" link at the bottom of the page
- Study the educational activity
- Complete the CME quiz and evaluation
- After successful completion of the CME quiz and evaluation, you will receive
the credit or participation certificate
*The CME quiz and evaluation must be completed by April 30, 2010, in order
to receive the credit or participation certificate.
Target Audience
Physicians who wish to advance their current knowledge of clinical cancer medicine
in FDA information, and are involved in providing patient care in a cancer care
environment.
Learning Objectives
After completing this course, the reader should be able to:
- Evaluate anthracycline tissue injury resulting from drug extravasation.
- Administer dexrazoxane in its new role of reducing extravasation tissue
injury.
- Describe the proposed mechanism of action of dexrazoxane for this use.
Accreditation and Credit Designation
This activity has been planned and implemented in accordance
with the Essential Areas and policies of the Accreditation Council for Continuing
Medical Education (ACCME) through the joint sponsorship of the School of Medicine
of The University of North Carolina at Chapel Hill and The Oncologist.
The School of Medicine of The University of North Carolina at Chapel Hill is accredited
by the ACCME to provide continuing medical education for physicians.
The School of Medicine of The University of North Carolina at Chapel Hill designates
this educational activity for a maximum of 1.00 AMA PRA Category 1 Credit™.
Physicians should only claim credit commensurate with the extent of their participation
in the activity.
Disclosure Policy
In compliance with the ACCME Standards of Commercial Support, it is the policy
of the School of Medicine of The University of North Carolina at Chapel Hill to
ensure balance, independence, objectivity, and scientific rigor in all of its
educational activities and to include information free of commercial bias and
based on the best evidence available. All individuals in a position to influence
the content of this activity have disclosed relevant financial interests or relationships
of their own, their spouse/partner, or their worksite, with manufacturers or providers
of commercial products, services, technology, or programs; and disclosed relationships
with current non-governmental supporters of the activity.
All information is submitted and reviewed and found to be scientifically rigorous,
based on the best available evidence, fair and balanced, and free of commercial
bias. All the recommendations involving clinical medicine in this CME activity
are based on evidence that is accepted within the profession of medicine as
adequate justification for their indications and contraindications in the care
of patients. All scientific research referred to, reported or used in CME in
support or justification of a patient care recommendation conforms to the generally
accepted standards of experimental design, data collection and analysis.
Any potential conflicts of interests are resolved via The Oncologist's anonymous
peer review process
All manuscripts are reviewed by the Editorial Board with ad hoc assistance from
two or more external experts in the field. All activity planners, authors, and
reviewers are required to submit conflict of interest forms. These forms accompany
the activity through the peer review process. Any reviewers who have a conflict
of interest are recused. When a reviewer is recused, other suitable reviewers
with no self-reported conflicts of interests are selected to conduct the reviews.
Editors’ disclosures are published annually online, whereas reviewers’
disclosures are held in confidence within the Editorial Office. All final publication
decisions are made by the Editorial Board. The acceptance of a manuscript is
based on its originality and importance to the field as assessed by the Editors.
Content Review
The content of this manuscript has been reviewed by independent peer reviewers to ensure that it is balanced, objective, and free from commercial bias.
Author Disclosure(s)
Robert C. Kane, M.D.
Credentials: Acting Deputy Division Director for Safety,
Division of Drug Oncology Products, Office of Oncology Drug Products, Center
for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver
Spring, Maryland, USA.
Disclosures: The author has indicated no relevant commercial
relationships.
W. David Jr. McGuinn, Jr., Ph.D.
Credentials: Pharmacologist, Division of Drug Oncology
Products, Office of Oncology Drug Products, Center for Drug Evaluation and
Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA.
Disclosures: The author has indicated no relevant commercial
relationships.
Ramzi Dagher, M.D.
Credentials: Deputy Director, Division of Drug Oncology
Products, Office of Oncology Drug Products, Center for Drug Evaluation and
Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA.
Disclosures: The author has indicated no relevant commercial
relationships.
Robert Justice, M.D.
Credentials: Division Director, Division of Drug Oncology
Products, Office of Oncology Drug Products, Center for Drug Evaluation and
Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA.
Disclosures: The author has indicated no relevant commercial
relationships.
Richard Pazdur, M.D.
Credentials: Office Director, Division of Drug Oncology
Products, Office of Oncology Drug Products, Center for Drug Evaluation and
Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA.
Disclosures: The author has indicated no relevant commercial
relationships.
Section Editors Disclosures
Jayne Gurtler, M.D., F.A.C.P., and Dwight Kaufman, M.D., Ph.D., have disclosed no financial relationships relevant to the content of this article.
CME Activity Director Disclosure
Frank M. Balis, M.D., CME Activity Director, has disclosed no financial relationships relevant to the content of this article.
Independent Peer Reviewers and Staff Managers Disclosures
No financial relationships relevant to the content of this article have been disclosed by the independent peer reviewers or staff managers.
Commercial Support
Non-governmental supporters of this The Oncologist CME
Online program: Abraxis BioScience, AstraZeneca, Bristol-Myers Squibb
Oncology, Merck, and sanofi-aventis
Hardware/Software Requirements
The Oncologist CME Online supports
the following browsers: Current production versions of Opera, Safari, Firefox,
Lynx and Mozilla; Netscape 6.1 and above, and Explorer 6.0 and above. The Macintosh
version of Explorer was discontinued in June 2003, and is not supported.
Other Links
Disclaimer
Privacy statement
Correspondence
The Oncologist CME Online
c/o AlphaMed Press
318 Blackwell Street, Suite 260
Durham, North Carolina 27701
Phone: (919) 680-0011
Fax: (919) 680-4411
Email: angela.davies{at}ucdmc.ucdavis.edu
Copyright © 2008 by AlphaMed Press.